Article Text

Download PDFPDF
Comparison of adverse drug reactions of statins in China from 1989 to 2019
  1. Leo Tsui1,
  2. Wei-Jie Liang2
  1. 1School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, Shanghai, China
  2. 2School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China
  1. Correspondence to Dr Leo Tsui, Shanghai University of Medicine and Health Sciences, Shanghai, Shanghai 201318, China; standhavemail{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Statin therapy has increased as a treatment for cardiovascular disease (CVD)1 but long-term use has been linked to adverse drug reactions (ADRs). Indeed, myopathy and hepatotoxicity are the most commonly reported ADRs in patients with long-term use of statins.2 However, our study demonstrates that, in the Chinese population from 1989 to 2019, gastrointestinal symptoms were the most common statin ADRs for hyperlipidaemia and other CVD treatments.3 To further compare the ADRs between statins taken by patients in China, we used analysis of variance (ANOVA) to determine whether the ADRs of individual statin groups differed.

We compared the difference in ADR ratios between statins based on the classification of ADRs (our Materials and Methods are shown in online supplemental materials). First, we calculated nine ADR ratios in each clinical trial, including overall, gastrointestinal, muscle, liver, neurological, CVD, skin, urinary and others. Second, we compared the difference in ADR ratios between six …

View Full Text


  • Contributors LT carried out literature searching, statistical analysis, drafting and submitting the manuscript. LT contributed to the interpretation of the results, revised the manuscript critically, and approved the final version of the manuscript. W-JL carried out the data extraction.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.